Citations

Clear

1792 citation(s) found for "Stephanie".

Incidence and management of pleural effusions in patients with Wilms tumor: A Pediatric Surgical Oncology Research Collaborative study
Al‐Hadidi, Ameer , Rinehardt, Hannah , Sutthatarn, Pattamon , Condon, Sienna, Chen, Stephanie , Wong‐Michalak, Shannon , Short, Scott S. , Meyers, Rebecka L. , Johnston, Michael E. , Zens, Tiffany , Dasgupta, Roshni , Calabro, Kristen , Piché, Nelson , Callas, Hannah, McKay, Katlyn G. , Lovvorn, Harold N. , Tracy, Elisabeth T. , Lund, Sarah , Polites, Stephanie F. , Davidson, Jacob , Dhooma, Janel, Seemann, Natashia M. , Marquart, John , Gainer, Haley , Lal, Dave R. , Rich, Barrie S. , Glick, Richard D. , Maloney, Lauren , Radu, Stephani, Fialkowski, Elizabeth , Kwok, Pei En , Romao, Rodrigo , Newman, Erika A. , Diehl, Thomas M. , Polcz, Valerie E., Petroze, Robin T. , Aldrink, Jennifer H. , Lautz, Timothy , Lund, Sarah B, Tracy, Elisabeth T , Aldrink, Jennifer H , Dasgupta, Roshni , Talbot, Lindsay J , Murphy, Andrew J. , Whitlock, Richard S. , Naik‐Mathuria, Bindi , Utria, Alan Fremder , Rothstein, David H. , Kim, Eugene S. , Kastenberg, Zachary J. , Malek, Marcus M. , Lautz, Timothy B. , Commander, Sarah Jane , Radu, Stephanie , Rubalcava, Nathan S. , Ehrlich, Peter F. , Le, Hau D. , Stanek, Joseph

Mayo Clinic

International Journal of Cancer | June 24, 2022 | Volume: 151 | Issue: 10 | Pages: 1696-1702

10.1002/ijc.34188 | PMID 35748343 Get It

AbstractWilms tumor (WT) is the most common renal malignancy in children. Children with favorable histology WT achieve survival rates of over 90%. Twelve percent of patients present with metastatic disease, most commonly to the lungs. The presence of a pleural effusion at the time of diagnosis of WT may be noted on staging imaging; however, minimal data exist regarding the significance and prognostic importance of this finding. The objectives of our study are to identify the incidence of pleural effusions in patients with WT, and to determine the potential impact on oncologic outcomes. A multi‐institutional retrospective review was performed from January 2009 to December 2019, including children with WT and a pleural effusion on diagnostic imaging treated at Pediatric Surgical Oncology Research Collaborative (PSORC) participating institutions. Of 1259 children with a new WT diagnosis, 94 (7.5%) had a pleural effusion. Patients with a pleural effusion were older than those without (median 4.3 vs 3.5 years; P = .004), and advanced stages were more common (local stage III 85.9% vs 51.9%; P < .0001). Only 14 patients underwent a thoracentesis for fluid evaluation; 3 had cytopathologic evidence of malignant cells. Event‐free and overall survival of all children with WT and pleural effusions was 86.2% and 91.5%, respectively. The rate and significance of malignant cells present in pleural fluid is unknown due to low incidence of cytopathologic analysis in our cohort; therefore, the presence of an effusion does not appear to necessitate a change in therapy. Excellent survival can be expected with current stage‐specific treatment regimens.
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra, Aaron , Gergoudis, Stephanie, Morales, George , Spyrou, Nikolaos , Shah, Jay , Kowalyk, Steven, Ayuk, Francis , Baez, Janna , Chanswangphuwana, Chantiya , Chen, Yi‐Bin , Choe, Hannah , DeFilipp, Zachariah , Gandhi, Isha , Holler, Ernst , Kapoor, Urvi , Kitko, Carrie L. , Lin, Jung-Yi, Pawarode, Attaphol , Rösler, Wolf, Schechter, Tal , Hyfte, Grace Van , Weber, Daniela , Wölfl, Matthias , Young, Rachel , Özbek, Umut , Ferrara, James L.M. , Hexner, Elizabeth , Lin, Jung-Yi , Merli, Pietro , Pulsipher, Michael A. , Qayed, Muna , Levine, John E , Spyrou, Nikolaos , Hexner, Elizabeth O. , Hogan, William J. , Kraus, Sabrina , Malki, Monzr M. Al , Reshef, Ran , Levine, John E.

Mayo Clinic

Blood Advances | June 23, 2022 | Volume: 6 | Issue: 12 | Pages: 3707-3715

10.1182/bloodadvances.2022007296 | PMID 35443021 Get It

Abstract We used a rigorous PRoBE (prospective-specimen collection, retrospective-blinded-evaluation) study design to compare the ability of biomarkers of systemic inflammation and biomarkers of gastrointestinal (GI) tissue damage to predict response to corticosteroid treatment, the incidence of clinically severe disease, 6-month nonrelapse mortality (NRM), and overall survival in patients with acute graft-versus-host disease (GVHD). We prospectively collected serum samples of newly diagnosed GVHD patients (n = 730) from 19 centers, divided them into training (n = 352) and validation (n = 378) cohorts, and measured TNFR1, TIM3, IL6, ST2, and REG3α via enzyme-linked immunosorbent assay. Performances of the 4 strongest algorithms from the training cohort (TNFR1 + TIM3, TNFR1 + ST2, TNFR1 + REG3α, and ST2 + REG3α) were evaluated in the validation cohort. The algorithm that included only biomarkers of systemic inflammation (TNFR1 + TIM3) had a significantly smaller area under the curve (AUC; 0.57) than the AUCs of algorithms that contained ≥1 GI damage biomarker (TNFR1 + ST2, 0.70; TNFR1 + REG3α, 0.73; ST2 + REG3α, 0.79; all P &lt; .001). All 4 algorithms were able to predict short-term outcomes such as response to systemic corticosteroids and severe GVHD, but the inclusion of a GI damage biomarker was needed to predict long-term outcomes such as 6-month NRM and survival. The algorithm that included 2 GI damage biomarkers was the most accurate of the 4 algorithms for all endpoints.
Succinct Cancer Clinical Trial Consent Forms in Rural Patients With Cancer: A Secondary Analysis of a Randomized, Double-Blinded study
Wieland, Jana, Satele, Daniel , Almodallal, Yahya , Novotny, Paul J. , Pritzl, Stephanie L., Mandrekar, Sumithra J. , Jatoi, Aminah , Novotny, Paul

Mayo Clinic

Journal of Patient Experience | June 22, 2022 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/23743735221107242 | PMID 35756962 Get It

Rural patients are often underrepresented in cancer clinical trials. This is a secondary analysis of a study that tested short (2000 word) versus long (6000 word) consent forms with a focus on rurality. Among 240 patients, 89 (37%) were rural. Seventy-one (80%) rural and 117 (77%) nonrural patients signed a consent form of any length ( P = .68). Forty-one of 47 (87%) rural patients signed a short consent form; in contrast, 30 of 42 (71%) signed a long form. These trends suggest rural patients are more likely to sign short consent forms. Further study is indicated.
Life-Threatening Complications of Influenza vs Coronavirus Disease 2019 (COVID-19) in US Children
Halasa, Natasha , Young, Cameron C. , Newhams, Margaret M. , Nakamura, Mari , Levy, Emily R. , Soma, Vijaya L, Talj, Rana, Fitzgerald, Julie C. , Mack, Elizabeth H. , Schuster, Jennifer E. , Coates, Bria M. , Hall, Mark W. , Schwarz, Adam J. , Kong, Michele, Spinella, Philip C. , Loftis, Laura L. , McLaughlin, Gwenn E., Rowan, Courtney M. , Nofziger, Ryan A. , Babbitt, Christopher , Bowens, Cindy , Flori, Heidi R. , Gertz, Shira J. , Zinter, Matt S. , Hume, Janet R. , Singh, Aalok R. , Crandall, Hillary A, Cullimore, Melissa L. , Patel, Manish M. , Randolph, Adrienne G. , Influenza, for the Pediatric Intensive Care, Investigators, Overcoming COVID-19, Kong, Michele, Gaspers, Mary Glas , Sanders, Ronald C., Irby, Katherine , Peter, Mourani, Harvey, Helen , Osborne, Christina , Sara, Shankman, Mourani, Peter M. , Port, Emily, Van, Kevin A, Carroll, Christopher L. , Tarquinio, Keiko M. , Coates, Bria M, Wellnitz, Kari , Bhoojhawon, Guru , Sullivan, Janice E, Bradford, Tamara T. , Riggs, Becky J. , Randolph, Adrienne G, Chen, Sabrina R., Carroll, Ryan W. , Yager, Phoebe H. , Heidemann, Sabrina M. , Hume, Janet R, Martin, Lora , Malloch, Lacy , Inagaki, Kengo , Schuster, Jennifer E, Kietzman, Abigail , Clouser, Katharine N. , Kleinman, Lawrence C. , Horwitz, Steven M. , Keenaghan, Michael , Doymaz, Sule , Walker, Tracie C. , Hall, Mark W, Lansell, Amanda , Staat, Mary Allen , Carcillo, Joseph A. , Smallcomb, Laura , Halasa, Natasha B, Stewart, Laura S , Romero, Yesenia, Hayek, Haya , Bowens, Cindy, Maamari, Mia , Crandall, Hillary , Smith, Lincoln , Kong, Michele , Young, Cameron C , Randolph, Adrienne G , Levy, Emily R , Spinella, Philip C , Kong, Michele , Hume, Janet R , Staat, Mary A , Gertz, Shira J , Spieker, Andrew J. , Olson, Samantha M. , Amarin, Justin Z. , Moffitt, Kristin , Weiss, Scott L. , Maddux, Aline B. , Schwartz, Stephanie P. , Kong, Michele, Hobbs, Charlotte V. , Bembea, Melania M. , Giuliano, John S. , Cvijanovich, Natalie Z , Thomas, Neal J. , Influenza, for the Pediatric Intensive Care, Investigators, Overcoming COVID-19, Kong, Michele, Typpo, Katri , Michelson, Kelly Nicole , Coates, Bria M, Sullivan, Janice E, Montgomery, Vicki , Havlin, Kevin , Randolph, Adrienne G, Fernandes, Neil D. , Hume, Janet R, Dhanrajani, Anita D. , Schuster, Jennifer E, Hill, Shannon, McCulloh, Russell J. , Li, Simon , Ratner, Adam J. , Dapul, Heda , Harwayne‐Gidansky, Ilana , Hymes, Saul , Hall, Mark W, Shein, Steven L. , Fink, Ericka L. , Halasa, Natasha B, Muñoz, Álvaro Coronado , Bowens, Cindy, McGuire, John K.

Mayo Clinic

Clinical Infectious Diseases | June 19, 2022 | Volume: 76 | Issue: 3 | Pages: e280-e290

10.1093/cid/ciac477 | PMID 35717646 Get It

Abstract Background Clinical differences between critical illness from influenza infection vs coronavirus disease 2019 (COVID-19) have not been well characterized in pediatric patients. Methods We compared demographics, clinical characteristics, and outcomes of US children (aged 8 months to 17 years) admitted to the intensive care or high-acuity unit with influenza or COVID-19. Using mixed-effects models, we assessed the odds of death or requiring life support for influenza vs COVID-19 after adjustment for age, sex, race and Hispanic origin, and underlying conditions including obesity. Results Children with influenza (n = 179) were younger than those with COVID-19 (n = 381; median, 5.2 years vs 13.8 years), less likely to be non-Hispanic Black (14.5% vs 27.6%) or Hispanic (24.0% vs 36.2%), and less likely to have ≥1 underlying condition (66.4% vs 78.5%) or be obese (21.4% vs 42.2%), and a shorter hospital stay (median, 5 days vs 7 days). They were similarly likely to require invasive mechanical ventilation (both 30.2%), vasopressor support (19.6% and 19.9%), or extracorporeal membrane oxygenation (2.2% and 2.9%). Four children with influenza (2.2%) and 11 children with COVID-19 (2.9%) died. The odds of death or requiring life support in children with influenza vs COVID-19 were similar (adjusted odds ratio, 1.30; 95% confidence interval, .78–2.15; P = .32). Conclusions Despite differences in demographics and clinical characteristics of children with influenza or COVID-19, the frequency of life-threatening complications was similar. Our findings highlight the importance of implementing prevention measures to reduce transmission and disease severity of influenza and COVID-19.
Decreasing Significance of Early Allograft Dysfunction with Rising Use of Nonconventional Donors
Ohara, Stephanie, Macdonough, Elizabeth , Egbert, Lena K. , Brooks, Abigail , Mathur, Amit K. , Aqel, Bashar , Reddy, Kunam S. , Jadlowiec, Caroline C. , Egbert, Lena, Mathur, Amit , Jadlowiec, Caroline , Lizaola‐Mayo, Blanca , Aqel, Bashar A.

Mayo Clinic

Medicina | June 17, 2022 | Volume: 58 | Issue: 6 | Pages: 821

10.3390/medicina58060821 | PMID 35744084 Get It

Background and Objectives: Early allograft dysfunction (EAD) is considered a surrogate marker for adverse post-liver transplant (LT) outcomes. With the increasing use of nonconventional donors, EAD has become a more frequent occurrence. Given this background, we aimed to assess the prevalence and impact of EAD in an updated cohort inclusive of both conventional and nonconventional liver allografts. Materials and Methods: Perioperative and one-year outcomes were assessed for a total of 611 LT recipients with and without EAD from Mayo Clinic Arizona. EAD was defined as the presence of one or more of the following: bilirubin > 10 mg/dL on day 7, INR > 1.6 on day 7, or ALT and/or AST > 2000 IU/L within the first 7 days of LT. Results: Within this cohort, 31.8% of grafts (n = 194) came from donation after circulatory death (DCD) donors, 17.7% (n = 108) were nationally shared, 16.4% (n = 100) were allocated as post-cross clamp, and 8.7% contained moderate steatosis. EAD was observed in 52.2% (n = 321) of grafts in the study cohort (79% in DCD grafts and 40% in DBD grafts). EAD grafts had higher donor risk index (DRI) scores (1.9 vs. 1.6, p < 0.0001), were more likely to come from DCD donors (48% vs. 13.8%, p < 0.0001), were regionally allocated (p = 0.003), and had higher cold ischemia times (median 6.0 vs. 5.5 h, p = 0.001). Primary nonfunction events were rare in both groups (1.3% vs. 0.3%, p = 0.22). Post-LT acute kidney injury occurred at a similar frequency in recipients with and without EAD (43.6% vs. 30.3%, p = 0.41), and there were no differences in ICU (median 2 vs. 1 day, p = 0.60) or hospital (6 vs. 5 days, p = 0.24) length of stay. For DCD grafts, the rate of ischemic cholangiopathy was similar in the two groups (14.9% EAD vs. 17.5% no EAD, p = 0.69). One-year patient survival for grafts with and without EAD was 96.0% and 94.1% (HR 1.2, 95% CI 0.7–1.8; p = 0.54); one-year graft survival was 92.5% and 92.1% (HR 1.0, 95% CI 0.7–1.5; p = 0.88). Conclusions: In this cohort, EAD occurred in 52% of grafts. The occurrence of EAD, however, did not portend inferior outcomes. Compared to those without EAD, recipients with EAD had similar post-operative outcomes, as well as one-year patient and graft survival. EAD should be managed supportively and should not be viewed as a deterrent to utilization of non-ideal grafts.
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer
Chakrabarti, Sakti , Starr, Jason S. , Innis-Shelton, Racquel, Shergill, Ardaman , Dada, Hiba I., Resta, Regina, Wagner, Stephanie A., Fei, Naomi , Starr, Jason Scott, Kasi, Pashtoon Murtaza , Chakrabarti, Sakti , Bucheit, Leslie

Mayo Clinic

Journal for ImmunoTherapy of Cancer | June 16, 2022 | Volume: 10 | Issue: 6 | Pages: e004485

10.1136/jitc-2021-004485 | PMID 35710297 Get It

Clinical trials reporting the robust antitumor activity of immune checkpoint inhibitors (ICIs) in microsatellite instability-high (MSI-H) solid tumors have used tissue-based testing to determine the MSI-H status. This study assessed if MSI-H detected by a plasma-based circulating tumor DNA liquid biopsy test predicts robust response to ICI in patients with pancreatic ductal adenocarcinoma (PDAC). Retrospective analysis of patients with PDAC and MSI-H identified on Guardant360 from October 2018 to April 2021 was performed; clinical outcomes were submitted by treating providers. From 52 patients with PDAC +MSI-H, outcomes were available for 10 (19%) with a median age of 68 years (range: 56–82 years); the majority were male (80%) and had metastatic disease (80%). Nine of 10 patients were treated with ICI. Eight out of nine patients received single-agent pembrolizumab (8/9), while one received ipilimumab plus nivolumab. The overall response rate by Response Evaluation Criteria in Solid Tumors was 77% (7/9). The median progression-free survival and overall survival were not reached in this cohort. The median duration of treatment with ICI was 8 months (range: 1–24), and six out of seven responders continued to show response at the time of data cut-off after a median follow-up of 21 months (range: 11–33). Tissue-based MSI results were concordant with plasma-based G360 results in five of six patients (83%) who had tissue-based test results available, with G360 identifying one more patient with MSI-H than tissue testing. These results suggest that detecting MSI-H by a well-validated liquid biopsy test could predict a robust response to ICI in patients with PDAC. The use of liquid biopsy may expand the identification of PDAC patients with MSI-H tumors and enable treatment with ICI resulting in improved outcomes.
NAA/Glu Ratio Associated with Suicidal Ideation in Pilot Sample of Autistic Youth and Young Adults
Moxon‐Emre, Iska , Croarkin, Paul E. , Daskalakis, Zafiris J. , Blumberger, Daniel M., Lyon, Rachael E. , Tani, Hideaki , Truong, Peter , Lai, Meng‐Chuan , Desarkar, Pushpal , Sailasuta, Napapon, Szatmári, Péter , Ameis, Stephanie H. , Croarkin, Paul E , Lai, Meng-Chuan , Blumberger, Daniel M.

Mayo Clinic

Brain Sciences | June 15, 2022 | Volume: 12 | Issue: 6 | Pages: 785

10.3390/brainsci12060785 | PMID 35741670 Get It

Suicidality is increased in autism spectrum disorder (ASD), yet effective interventions are lacking. Developing biologically based approaches for preventing and treating suicidality in ASD hinges on the identification of biomarkers of suicidal ideation (SI). Here, we assessed magnetic resonance spectroscopy (MRS) markers of glutamatergic neurotransmission in ASD youth and young adults. Twenty-eight ASD participants (16–33 years) underwent 1H-MRS, and metabolites were quantified using LCModel. N-acetylaspartate (NAA), glutamate (Glu), and the NAA/Glu ratio from the left dorsolateral prefrontal cortex were compared between ASD SI+ (n = 13) and ASD SI− (n = 15) participants. We found that ASD SI+ participants had a higher NAA/Glu ratio compared ASD SI- participants. The NAA/Glu ratio also predicted SI and significantly discriminated between ASD SI+/SI− participants. All analyses including NAA and Glu alone were non-significant. Here, we provide preliminary evidence for the importance of NAA/Glu in ASD with SI, with implications for biomarker discovery. Further mechanistic research into risk and interventional approaches to address SI in ASD are needed.
Understanding the Care Journey and Needs of Advanced Fetal Care Center Patients
Ylvisaker, Heidi, Beh, Megan, Liechty, Kenneth W. , Velasco, Pamela, Dion, Éric , Snowise, Saul , Lillegard, Joseph B. , Feltis, Brad A. , Eyerly‐Webb, Stephanie A. , Lim, Foong‐Yen Y.

Mayo Clinic

The Permanente Journal | June 15, 2022 | Volume: 26 | Issue: 2 | Pages: 11-20

10.7812/tpp/21.189 | PMID 35933663 Get It

Interactive Inflammatory Bowel Disease Biologics Decision Aid Does Not Improve Patient Outcomes Over Static Education: Results From a Randomized Trial
Almario, Christopher V. , Deen, Welmoed K. van , Gale, Rebecca, Sidorkiewicz, Stéphanie , Choi, So Yung , Bonthala, Nirupama , Ha, Christina , Syal, Gaurav , Dupuy, Taylor , Melmed, Gil , Spiegel, Brennan , Melmed, Gil Y , Spiegel, Brennan , Chen, Michelle , Liu, Xiaoyu

Mayo Clinic

American Journal of Gastroenterology | June 13, 2022 | Volume: 117 | Issue: 9 | Pages: 1508-1518

10.14309/ajg.0000000000001866 | PMID 35973146 Get It

INTRODUCTION: To support shared decision-making (SDM) between patients and providers surrounding biologic treatments, we created IBD&me (ibdandme.org)—a freely available, unbranded, interactive decision aid. We performed a multicenter comparative effectiveness trial comparing the impact of IBD&me on SDM vs a biologics fact sheet developed by the Crohn's & Colitis Foundation. METHODS: We enrolled patients with inflammatory bowel disease (IBD) being seen at a clinic within IBD Qorus—a multicenter adult IBD learning health system—between March 5, 2019, and May 14, 2021. Eligible patients included those with recent IBD-related symptoms who reported that they wanted to discuss biologics with their provider during their upcoming visit. Patients were randomized 1:1 using stratified block randomization and received an e-mail 1 week before their visit inviting them to review either IBD&me or a fact sheet. The primary outcome was patient perception of SDM as measured by the 9-Item SDM Questionnaire (0–100 scale; higher = better); the Student t test was used to compare outcomes between arms. RESULTS: Overall, 152 patients were randomized (biologics fact sheet 75, IBD&me 77); most patients had Crohn's disease (66.4%) and were biologic-experienced (82.9%). No differences were seen between groups regarding SDM (fact sheet 72.6 ± 25.6, IBD&me 75.0 ± 20.8; P = .57). Most patients stated they would be likely to recommend the fact sheet (79.6%) or IBD&me (84.9%; P = .48) to another patient with IBD. DISCUSSION: No differences in outcomes were seen between IBD&me and the biologics fact sheet in this comparative effectiveness study; patients reported high satisfaction with both resources. Further study, particularly among biologic naïve patients, is needed to determine the utility of interactive components to IBD decision aids.
Progressive White Matter Injury in Preclinical Dutch Cerebral Amyloid Angiopathy
Shirzadi, Zahra , Yau, Wai‐Ying Wendy , Schultz, Stephanie A. , Scott, Matthew R. , Goubran, Maged , Mojiri‐Forooshani, Parisa, Joseph‐Mathurin, Nelly , Kantarci, Kejal , Preboske, Greg M., Taddei, Kevin , Sohrabi, Hamid R. , Johnson, Keith A. , Bateman, Randall J. , Martins, Ralph N. , Greenberg, Steven M. , Chhatwal, Jasmeer P. , Investigators, DIAN, Vöglein, Jonathan , Yau, Wai-Ying W , Joseph-Mathurin, Nelly , Kantarci, Kejal , Preboske, Greg, Bateman, Randall J , Vöglein, Jonathan , Schultz, Aaron P. , Wermer, Marieke J H , Jack, Clifford R. , Benzinger, Tammie L.S. , Sperling, Reisa Anne , Investigators, DIAN

Mayo Clinic

Annals of Neurology | June 7, 2022 | Volume: 92 | Issue: 3 | Pages: 358-363

10.1002/ana.26429 | PMID 35670654 Get It

Autosomal‐dominant, Dutch‐type cerebral amyloid angiopathy (D‐CAA) offers a unique opportunity to develop biomarkers for pre‐symptomatic cerebral amyloid angiopathy (CAA). We hypothesized that neuroimaging measures of white matter injury would be present and progressive in D‐CAA prior to hemorrhagic lesions or symptomatic hemorrhage. In a longitudinal cohort of D‐CAA carriers and non‐carriers, we observed divergence of white matter injury measures between D‐CAA carriers and non‐carriers prior to the appearance of cerebral microbleeds and >14 years before the average age of first symptomatic hemorrhage. These results indicate that white matter disruption measures may be valuable cross‐sectional and longitudinal biomarkers of D‐CAA progression. ANN NEUROL 2022;92:358–363